)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Monte Rosa Therapeutic
Monte Rosa Therapeutic (GLUE) investor relations material
Monte Rosa Therapeutic Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Q3 collaboration revenue was $54.4M, primarily from a $50M Novartis milestone; net income was $3.1M versus a $27.1M loss YoY.
Nine-month revenue was $67.5M and net loss was $84.8M; R&D investment continued to advance clinical and discovery programs.
Cash, cash equivalents, restricted cash and marketable securities totaled $582.6M at September 30, 2026; management expects runway into 2029.
Financial highlights
Q3 revenue rose to $54.4M from $12.8M YoY, primarily reflecting the $50M Novartis Sjögren’s disease milestone.
Q3 R&D was $45.4M versus $36.7M, and G&A was $10.9M versus $9.1M; operating expenses increased to $56.3M from $45.7M.
Q3 net income was $3.1M versus a $27.1M net loss in Q3 2025.
Nine-month revenue declined to $67.5M from $120.9M, reflecting the prior-year Novartis upfront payment; net loss was $84.8M versus net income of $7.5M.
Nine-month R&D rose to $137.4M from $99.5M and G&A to $31.3M from $25.9M.
Outlook and guidance
GEMINI-1 Phase 2 in gout is expected to start in Q4 2026, with initial data in H2 2027; GFORCE-2 in stable CAD and GALAXY-1 in hidradenitis suppurativa are expected to start in H1 2027.
MRT-2359 updates are expected by year-end 2026 for the enzalutamide expansion arm and in 2027 for MODEFIRe-1; CDK2- and CCNE1-directed MGD IND submissions are expected in 2027.
Cash, cash equivalents, restricted cash and marketable securities are expected to support operations into 2029.
R&D, G&A and capital expenditures are expected to increase as clinical trials, manufacturing and pipeline development advance.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Monte Rosa Therapeutic
- MRT-8102 showed potent NEK7 degradation, biomarker normalization, and strong safety in Phase I.GLUE
Study result - Advancing targeted protein degraders in inflammation, autoimmune, and oncology with strong financial runway.GLUEWells Fargo 21st Annual Healthcare Conference
- Advancing three first-in-class MGD programs with strong pharma partnerships and robust clinical data.GLUECorporate presentation
- Q2 2026 net loss rose on lower collaboration revenue and higher R&D; cash runway extends to 2029.GLUEQ2 2026
- Pipeline advances in oncology and autoimmunity set up major clinical milestones for the coming year.GLUEJefferies Global Healthcare Conference 2025
- Strong clinical progress and strategic interest drive momentum for molecular glue degrader programs.GLUEJefferies Global Healthcare Conference 2026
- Molecular glue degraders advance in oncology and inflammation, with key trials set for 2024.GLUE7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
- Advancing selective oral degraders in immunology and oncology with strong clinical and financial momentum.GLUECorporate presentation
- Strong pipeline progress, Novartis deal, and $377M cash position support growth into 2028.GLUEQ4 2024
Next Monte Rosa Therapeutic earnings date
3rd Annual Guggenheim Healthcare Innovation Conference9 Nov, 2026
Monte Rosa Therapeutic
Next Monte Rosa Therapeutic earnings date
3rd Annual Guggenheim Healthcare Innovation Conference9 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Monte Rosa Therapeutics Inc. is a clinical-stage biotechnology company focused on developing molecular glue degraders (MGDs). These small molecules are designed to selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation processes. The company targets a range of therapeutic areas, including oncology, autoimmune, and inflammatory diseases. Monte Rosa utilizes its proprietary QuEEN platform, which integrates proteomics, structural biology, AI, and machine learning, to rapidly identify and develop highly selective protein degraders. The company operates out of Boston, Massachusetts, with additional research facilities in Basel, Switzerland. Its shares trade on the NASDAQ.